Abstract

Assessing the tolerability and toxicity of Levatinib plus Pembrolizumab for recurrent endometrial cancer: A real world experience (1110)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call